Indian News Maker Press Release Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR



Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.  Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.

It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.

  • Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
  • Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
  • Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
  • Higher viral load reduction was observed in Molnupiravir+ SoC arm
  • No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms

 Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.

Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.

7 thoughts on “Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR”

  1. Its such as you read my thoughts! You seem to grasp so much approximately this, like you wrote the e-book
    in it or something. I think that you just can do with a few p.c.
    to pressure the message home a bit, but other than that, that is great blog.
    A fantastic read. I’ll certainly be back.

  2. tinyurl.com says:

    Excellent beat ! I would like to apprentice whilst you amend your website, how
    could i subscribe for a weblog site? The account helped me a acceptable deal.
    I had been a little bit acquainted of this your broadcast provided shiny clear idea

  3. Attractive component to content. I simply stumbled upon your blog and in accession capital
    to claim that I get in fact enjoyed account your weblog posts.
    Any way I’ll be subscribing for your feeds or even I achievement you get entry to consistently rapidly.

  4. Hey there I am so thrilled I found your weblog, I really
    found you by mistake, while I was looking on Bing for something else,
    Regardless I am here now and would just like to
    say cheers for a tremendous post and a all round exciting blog
    (I also love the theme/design), I don’t have time to go
    through it all at the moment but I have bookmarked it and also added your RSS feeds,
    so when I have time I will be back to read a lot more, Please do keep up the superb job.

  5. gamefly says:

    Wow! In the end I got a weblog from where I be able to genuinely
    get helpful facts regarding my study and knowledge.

  6. tinyurl.com says:

    Hi! Someone in my Myspace group shared this website with us
    so I came to take a look. I’m definitely loving the information. I’m bookmarking and
    will be tweeting this to my followers! Superb blog and wonderful style and design.

  7. Right here is the right website for everyone who would like to find out about this
    topic. You understand a whole lot its almost tough to argue with you (not that
    I really will need to…HaHa). You certainly put a new
    spin on a subject which has been written about for many years.

    Excellent stuff, just great!

Leave a Reply

Your email address will not be published.